

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has confirmed that the shortage for Sandoz Fesoterodine Fumarate 4 mg Extended-Release Tablet (DIN 02521768) manufactured by Sandoz Canada Inc. has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 25, 2023**. The following grouping was removed from the Critical Supply Product List **April 25, 2023**.

FESOTERODINE FUMARATE

MG EXTENDED-RELEASE TABLET

00002521768	SANDOZ FESOTERODINE	SDZ	\$ 1.1250
00002380021	TOVIAZ	PFI	\$ 1.5500

Removal of Temporary Benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Hydromorphone 2 mg/mL Injection (DIN 02145901) manufactured by Sandoz Canada Inc., Hydromorphone HCL 2 mg/mL Injection (DIN 02460602) manufactured by Sterimax Inc. and Hydromorphone Hydrochloride 1 mg/mL Injection (DIN 02514435) manufactured by Sandoz Canada Inc. were added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage for of Hydromorphone 2 mg/mL Injection (DIN 02145901) has been resolved.

Hydromorphone HCL 2 mg/mL Injection (DIN 02460602) and **Hydromorphone Hydrochloride 1 mg/mL Injection (DIN 02514435)** will no longer be considered temporary benefits for the ADBL after **May 29, 2023**. The above grouping was removed from the Critical Supply Product List **April 27, 2023**.

Due to the shortages of Sandoz Levofloxacin 250 mg and 500 mg Tablet (DIN 02298635, 02298643) manufactured by Sandoz Canada Inc., Act-Levofloxacin 250 mg and 500 mg Tablet (DIN 02315424, 02315432) manufactured by Teva Canada Limited and Apo-Levofloxacin 250 mg and 500 mg Tablet (DIN 02284707, 02284715) manufactured by Apotex Inc., Riva-Levofloxacin 250 mg Tablet (DIN 02492725) manufactured by Laboratoire Riva Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. and Teva Canada Limited have advised Alberta Blue Cross that the shortages of Sandoz Levofloxacin 250 mg Tablet (DIN 02298635) and Act-Levofloxacin 250 mg and 500 mg Tablet (DIN 02315424, 02315432), respectively have been resolved.

continued next page

continued from previous page

Riva-Levofloxacin 250 mg Tablet (DIN 02492725) will no longer be considered a temporary benefit for the *ADBL* after **May 29, 2023**. The above grouping was removed from the Critical Supply Product List **April 27, 2023**.

Due to the shortages of Jamp Spironolactone 100 mg Tablet (DIN 02518848) manufactured by Jamp Pharma Corporation, Mint-Spironolactone 100 mg Tablet (DIN 02488159) manufactured by Mint Pharmaceuticals Inc., and Teva-Spironolactone 100 mg Tablet (DIN 00613223) manufactured by Teva Canada Limited, Aldactone 100 mg Tablet (DIN 00285455) manufactured by Pfizer Canada ULC was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Mint Pharmaceuticals Inc. has advised Alberta Blue Cross that the shortage of Mint-Spironolactone 100 mg Tablet (DIN 02488159) has been resolved.

Aldactone 100 mg Tablet (DIN 00285455) will no longer be considered a temporary benefit for the *ADBL* after **May 29, 2023**. The above grouping was removed from the Critical Supply Product List **April 27, 2023**.

Temporary Benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Apo-Medroxy 10 mg Tablet (DIN 02277298) manufactured by Apotex Inc. and Teva-Medroxyprogesterone 10 mg Tablet (DIN 02221306) manufactured by Teva Canada Limited, Provera 10 mg Tablet (DIN 00729973) manufactured by Pfizer Canada ULC. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **April 25, 2023**.

As of **April 25, 2023**, all claims for **Provera 10 mg Tablet (DIN 00729973)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php

Due to the unavailability of Jamp-K Effervescent 975 mg (25 MEq) Tablet (NPN 80033602) manufactured by Jamp Pharma Corporation, K-Lyte Orange Flavored 25 MEq Effervescent Tablet (NPN 02085992) manufactured by Wellspring Pharmaceutical Canada Corp. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **May 2, 2023**.

As of May 2, 2023, all claims for **K-Lyte Orange Flavored 25 MEq Effervescent Tablet (NPN 02085992)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

